NCT01106950 2017-12-28Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)Masonic Cancer Center, University of MinnesotaPhase 2 Terminated15 enrolled 12 charts